MEDIGENE AG NA O.N. chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.28
Dividend & YieldN/A€ (N/A)
Beta 1.01
Market capitalization 52.81M
Operating cash flow 13.93M
ESG Scores unknown

Company description

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 633k 15k -939k 65k
Total Cashflows From Investing Activities -19.47M 24.17M 21.12M 4.03M
Net Borrowings -730k -490k -826k -1.03M
Total Cash From Financing Activities 29.3M -469k -826k -1.03M
Change To Operating Activities 3.43M 797k -4.57M -5.66M
Issuance Of Stock 32.44M 21k
Net Income -21.23M -19.96M -28.88M -9.98M
Change In Cash -316k 7.27M -4.65M -7.62M
Effect Of Exchange Rate -155k -155k -155k 144k
Total Cash From Operating Activities -10.14M -16.42M -24.79M -10.75M
Depreciation 1.57M 2.37M 4.26M 3.43M
Change To Account Receivables 605k 341k 2.65M 914k
Other Cashflows From Financing Activities -2.41M
Change To Netincome 4.42M -291k 2.69M 484k
Capital Expenditures -1.01M -1.43M -484k -125k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 17.12M 22.62M 22.26M 12.8M
Income Before Tax -21.68M -19.92M -28.4M -10.28M
Net Income -21.23M -19.96M -28.88M -9.98M
Selling General Administrative 7.62M 7.79M 8.56M 6.84M
Gross Profit 2.05M 10.13M 6.71M 9.1M
Ebit -22.51M -20.16M -27.2M -10.01M
Operating Income -22.51M -20.16M -27.2M -10.01M
Interest Expense -139k -450k -399k -344k
Income Tax Expense -454k 44k 472k -300k
Total Revenue 7.58M 10.51M 8M 10.46M
Cost Of Revenue 5.53M 383k 1.29M 1.36M
Total Other Income ExpenseNet 828k 243k -1.21M -277k
Net Income From Continuing Ops -21.23M -19.96M -28.88M -9.98M
Net Income Applicable To Common Shares -21.23M -19.96M -28.88M -9.98M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 21.67M 27.39M 21.6M 14.65M
Total Stockholder Equity 103.25M 81.82M 53.15M 44.82M
Other Current Liabilities 5.61M 7.78M 7.36M 4.84M
Total Assets 124.91M 109.22M 74.75M 59.47M
Common Stock 24.56M 24.56M 24.56M 24.56M
Other Current Assets 2.7M 529k 286k 20k
Retained Earnings -402.86M -422.83M -451.7M -461.68M
Treasury Stock 481.56M 480.09M 480.29M 481.94M
Cash 27.41M 34.68M 30.03M 22.42M
Total Current Liabilities 8.82M 10.22M 10.13M 8.03M
Other Stockholder Equity 481.56M 480.09M 480.29M 481.94M
Property, Plant, and Equipment 4.26M 8.82M 6.88M 4.9M
Total Current Assets 57.52M 57.73M 32.7M 24.16M
Net Tangible Assets 67.02M 46.12M 21.52M 14.7M
Net Receivables 3.49M 2.02M 1.96M 1.33M
Accounts Payable 1.36M 1.37M 433k 498k


Insider Transactions

Here are the insider transactions of stock shares related to MEDIGENE AG NA O.N.:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to MEDIGENE AG NA O.N.. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on MEDIGENE AG NA O.N.

Here is the result of two systematic investment strategies applied to MEDIGENE AG NA O.N.. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on MEDIGENE AG NA O.N.

The following chart shows the equity curve of the two systematic investment strategies applied to MEDIGENE AG NA O.N.:

MEDIGENE AG NA O.N. automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -32.63% on the backtest period.

Performance at glance

Performance

-32.63 %

Latent gain

-489.93 €

Invested capital

1501.6 €

Annualized return

-7.96 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on MEDIGENE AG NA O.N.

This is the result of two momentum investment strategies applied to MEDIGENE AG NA O.N.. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on MEDIGENE AG NA O.N.

The following chart shows all the entries opened by the momentum investment system on MEDIGENE AG NA O.N.:

MEDIGENE AG NA O.N. momentum entries
  • The first momentum investment strategy would give -35.62% of return on MEDIGENE AG NA O.N.. That represents -1696.74€ of latent gain with 4763.49€ of employed capital.
  • The second momentum investment strategy would give -37.08% of return on MEDIGENE AG NA O.N.. That represents -1113.58€ of latent gain with 3002.97€ of employed capital.
Performance at glance (1Q Momentum)

Performance

-35.62 %

Latent gain

-1696.74 €

Invested capital

4763.49 €

Annualized return

-2.81 %
Performance at glance (2Q Momentum)

Performance

-37.08 %

Latent gain

-1113.58 €

Invested capital

3002.97 €

Annualized return

-10.24 %

Momentum equity curve on MEDIGENE AG NA O.N.

The following chart shows the equity curve of the two momentum strategies applied to MEDIGENE AG NA O.N.:

MEDIGENE AG NA O.N. momentum equity

Note: the dividends potentially given by MEDIGENE AG NA O.N. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on MEDIGENE AG NA O.N.

The following chart shows the employed capital evolution of the two momentum strategies on MEDIGENE AG NA O.N. since the beginning:

MEDIGENE AG NA O.N.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on MEDIGENE AG NA O.N.

Buy the dip entry openings on MEDIGENE AG NA O.N.

MEDIGENE AG NA O.N.

The performance achieved by the robo-advisor on MEDIGENE AG NA O.N. is -5.91%. That represents -59.12$ of latent gain with 1000.29€ of employed capital. The following chart shows MEDIGENE AG NA O.N. stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of MEDIGENE AG NA O.N., and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-5.91 %

Latent gain

-59.12 €

Invested capital

1000.29 €

Annualized return

-2.81 %

Equity curve of the strategy applied to MEDIGENE AG NA O.N.

The following chart shows the result of the investment strategy applied to MEDIGENE AG NA O.N.:

MEDIGENE AG NA O.N.

Note: the dividends potentially given by MEDIGENE AG NA O.N. are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on MEDIGENE AG NA O.N.

The following chart shows the employed capital evolution since the beginning of the investment strategy on MEDIGENE AG NA O.N.:

MEDIGENE AG NA O.N.

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on MEDIGENE AG NA O.N.

In this section, I will compare the three previous investment strategies applied to MEDIGENE AG NA O.N..

Equity curve comparison on MEDIGENE AG NA O.N.

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

MEDIGENE AG NA O.N. investment strategy comparison

Employed capital comparison on MEDIGENE AG NA O.N.

MEDIGENE AG NA O.N. investment comparison

Performance comparison on MEDIGENE AG NA O.N.

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -32.63% -489.93€ 1501.6€ -7.96%
Momentum 1 quarter -35.62% -1696.74€ 4763.49€ -9.23%
Momentum 2 quarters -37.08% -1113.58€ 3002.97€ -10.24%
Non-directional -5.91% -59.12€ 1000.29€ -2.81%
Annualized return comparison

Automatic investment

-7.96 %

Momentum 1Q

-10.24 %

Momentum 2Q

-10.24 %

Non-directional

-2.81 %

Correlated stocks

Here are the most positively and negatively correlated stocks with MEDIGENE AG NA O.N.:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between MEDIGENE AG NA O.N. and the other stocks. There may be false positives or some missing correlated stocks. If the price of MEDIGENE AG NA O.N. does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name MEDIGENE AG NA O.N.
Country Germany
City Munich
Address Lochhamer Strasse 11
Phone 49 89 2000 330
Website www.medigene.com
FullTime employees 61
Industry Biotechnology
Sector Healthcare
Exchange XETRA
Ticker MDG1.XETRA
Market www.xetra.com

MEDIGENE AG NA O.N. ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown